BRAF Antikörper

Produktnummer ABIN7863851

Der Maus Monoklonal anti-BRAF Antikörper (Klon BRAF-1626) (ABIN7863851) detektiert spezifisch BRAF in WB und IHC. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für BRAF Antikörper (ABIN7863851)

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser BRAF Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Klon: BRAF-1626

Produktdetails anti-BRAF Antikörper

Verwendungszweck: BRAF Antibody

Spezifität: The 79oΩBRAF 79oΩgene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The 79oΩBRAF 79oΩV600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas. 79oΩFurthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia, 79oΩ54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytoses 79oΩand 60 % of pleomorphic xanthoastrocytomas. 79oΩ

Aufreinigung: 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

Immunogen: Recombinant fragment of human HMG20B protein (exact sequence is proprietary)

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 200 μg/mL

Buffer: Prepared in 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C.Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Details zu BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Andere Bezeichnung: BRAF

Hintergrund:

BRAF25, BRAF35, BRCA2-associated factor 35, High Mobility Group Protein 20B (HM20B), HMG box-containing protein 20B, HMG domain-containing protein HMGX2, HMG20B, SMARCE1-related protein, SMARCE1r, Sox-like transcriptional factor, SOXL

A431, Jurkat and HeLa cells. Melanoma or Colon Carcinoma, Human Lung, Small Intestine, Gallbladder, Pancreas tissue

Molekulargewicht: 35kDa (predicted)

Gen-ID: 673, 406534

UniProt: Q9P0W2

Pathways: MAPK Signalweg, RTK Signalweg, Neurotrophin Signalübertragung, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagie